Popular Articles
Revitol Cellulite Cream

Internists And Other Physician Groups Support Comparative Effectiveness Provisions In Proposed Legislation
The American College of Physicians (ACP) joined with two other physician groups to offer strong support for the Comparative Effectiveness Research (CER) provisions included in the Tri-Committee health reform bill about to be considered in the House. The Tri-Committee, which unveiled its proposed legislation on June 19, is made up of the House Ways and Means, Energy and Commerce, and Education and Labor Committees. Don't forget to buy zoloft online no prescription.

New Hampshire Officials: Need For Mental Health Services Increasing
In New Hampshire, Foster"s Daily Democrat reports: "As unemployment statistics increase and the economic climate deteriorates, a large group of people who would otherwise likely not need mental health services are finding themselves at an increased risk for depression, anxiety, compulsive behaviors and substance abuse, according (to) the Substance Abuse and Mental Health Services Administration, a division of the U.S. Department of Health and Human Services."

generic viagra online


News of the day
Health Subcommittee Considers Bill To Eliminate Pre-Emption For Medical Devices
The House Energy and Commerce Health Subcommittee on Tuesday heard testimony on the Medical Device Safety Act of 2009 (HR 1346), which would allow consumers to sue medical device manufacturers in state courts, CQ HealthBeat reports. The bill responds to last year"s Supreme Court ruling that says medical devices with FDA pre-marketing approval can be pre-empted from lawsuits under state law, in accordance with the Medical Device Amendments of 1976. Rep. Frank Pallone (D-N.Y.), who introduced the bill, said that the 2008 Supreme Court ruling "ignor[ed] congressional intent" by providing blanket immunity for medical device makers. According to Rep. John Dingell (D-Mich.), a co-sponsor of the bill, the original 1976 law sought to grant regulatory authority to FDA for medical devices, but it did not aim to eliminate state liability. Committee Chair Rep. Henry Waxman (D-Calif.), another co-sponsor, said last year"s ruling already has caused 1,400 injury cases to be thrown out of court, adding that the threat of litigation provides manufacturers with additional safety incentives. David Vladeck -- a law professor at Georgetown University Law Center who testified at the hearing -- added that immunity from lawsuits "removes incentive to manufacturers to fix devices quickly and get defective devices off the market."Rep. Nathan Deal (R-Ga.) said the class of device that must obtain pre-marketing approval -- which includes pacemakers and replacement heart valves -- represents only 2% of all approved medical devices each year. Rep. Michael Burgess (R-Texas) added that the measure could create an inconsistent system that allows both FDA experts and jurors in various states to make decisions on medical device safety standards. In addition, Rep. Joe Pitts (R-Pa.) cautioned that the bill might encourage manufacturers to limit distribution of their devices to certain states (Kim, CQ HealthBeat, 5/13). Related Editorial
Sexual Health

New Data Show Cost Savings Achieved By Treating Mild And Moderate Alzheimer's Patients With Aricept(R)

Researchers attending the annual meeting of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR), heard today that prescribing Aricept® (donepezil hydrochloride) as soon as patients are diagnosed with either mild or moderate Alzheimer"s disease saves the NHS money. The findings contradict the recommendation by NICE that these medicines are not cost effective in the early stages of the disease, a decision that has been the subject of much recent debate. The study shows that direct savings to the NHS over a ten year period average over ÷£4,000 per patient for those starting treatment in the mild stages of the disease. Total savings to society rise to ÷£7,100 per patient when the cost of care giver"s time is included. The average direct saving to the NHS over the same period for patients across the mild and moderate stages of the disease was estimated to be ÷£2,300 per patient, and for society ÷£4,800 when care giver"s time is taken into account. The study, sponsored by Eisai, uses more accurate calculations and more up-to-date costs of Alzheimer"s disease treatment than were used in the analyses undertaken by NICE, and the authors conclude that their findings indicate the decision taken by NICE to restrict treatment to patients with moderate Alzheimer"s disease was highly questionable. ISPOR


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):